How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,896 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Association of Psoriasis With Comorbidity Development in Children With Psoriasis. Full Text available with Trip Pro

Association of Psoriasis With Comorbidity Development in Children With Psoriasis. Children with psoriasis are at increased risk for comorbidities. Many children with psoriasis are also overweight or obese; it is unknown whether the increased risk of comorbidities in these children is independent of obesity.To determine the risk of elevated lipid levels (hyperlipidemia/hypertriglyceridemia), hypertension, metabolic syndrome, polycystic ovarian syndrome, diabetes, nonalcoholic liver disease (...) , and elevated liver enzyme levels in children with and without psoriasis, after accounting for obesity.This was a retrospective cohort study of claims data from Optum Laboratories Data Warehouse (includes 150 million privately insured and Medicare enrollees). A cohort of 29 957 children with psoriasis (affected children) and an age-, sex-, and race-matched comparator cohort of 29 957 children without psoriasis were identified and divided into 4 groups: (1) nonobese, without psoriasis (reference cohort); (2

2018 JAMA dermatology (Chicago, Ill.)

122. Prevalence of genital psoriasis in patients with psoriasis. Full Text available with Trip Pro

Prevalence of genital psoriasis in patients with psoriasis. Psoriatic lesions in the genital area (GenPs) can cause considerable physical and emotional distress. To increase physician awareness, we estimated the GenPs prevalence among patients with psoriasis.An English language literature search was performed. Articles reporting GenPs prevalence met the search criteria and were included. Because GenPs is rarely reported in demographics of prospective clinical trials, GenPs prevalence (...) and baseline demographics of patients with and without GenPs in two prospective randomized phase 3b trials (NCT02561806 and NCT02634801) involving patients with moderate-to-severe psoriasis are reported.Overall, 600 references were screened. Eighteen articles met the search criteria. Patient populations were highly heterogeneous across articles. Broadly, the presence of GenPs was either physician-reported (physical examinations) or patient-reported (questionnaires). In the literature, GenPs prevalence

2018 Journal of Dermatological Treatment

123. Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. Full Text available with Trip Pro

Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. Optimal clinical management of psoriasis and psoriatic arthritis (PsA) Optimal clinical management of psoriasis and psoriatic arthritis (PsA) requires understanding of the impact on patients. The NORdic PAtient survey of Psoriasis and PsA (NORPAPP) aimed to obtain current data on disease prevalence (...) and patient perceptions in Sweden, Denmark and Norway. Among 22,050 individuals questioned, the reported prevalence of psoriasis and/or PsA was 9.7% (5.7% physician-diagnosed plus 4.0% self-diagnosed only); prevalence was similar in Sweden (9.4%) and Denmark (9.2%) but significantly higher in Norway (11.9%). Of those reporting a physician's diagnosis, 74.6% reported psoriasis alone, 10.3% PsA alone and 15.1% both. Patients with PsA perceived their disease to be more severe than those with psoriasis

2018 Acta Dermato-Venereologica

124. CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents. (Abstract)

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents. Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities, such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular diseases. These factors have a significant impact on the decision to use one therapy over another. The past decade has seen a paradigm shift in our understanding of the pathogenesis of psoriasis that has led (...) to identification of new therapeutic targets. Several new drugs have gained approval by the US Food and Drug Administration, expanding the psoriasis armamentarium, but still a large number of patients continue to be untreated or undertreated. Treatment regimens for psoriasis patients should be tailored to meet the specific needs based on disease severity, the impact on quality of life, the response to previous therapies, and the presence of comorbidities. The first article in this continuing medical education

2018 Journal of American Academy of Dermatology

125. Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab. (Abstract)

Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab. We sought to determine the psoriatic nail feature which responds to ustekinumab treatment more effectively, and evaluate which between the Nail Psoriasis Severity Index (NAPSI) and the Nijmegen-Nail psoriasis Activity Index tooL (N-NAIL) better reflects the clinical improvement of nail psoriasis.Thirty patients with moderate-to-severe plaque (...) psoriasis were prospectively enrolled and treated with ustekinumab for 52 weeks. A single investigator evaluated the condition using the NAPSI and the N-NAIL with serial fingernail photographs.Of the 30 patients, 13 (43.3%) had fingernail psoriasis present at baseline. Mean NAPSI scores improved from 9.46 ± 8.7 at baseline to 6.00 ± 5.2 at week 52, but the improvement was not statistically significant (p = .09). Mean N-NAIL scores significantly improved from 5.46 ± 5.1 at baseline to 3.92 ± 3.7 at week

2018 Journal of Dermatological Treatment

126. Patient Perceptions of Clear/Almost Clear Skin in Moderate-to-Severe Plaque Psoriasis: Results of the Clear About Psoriasis Worldwide Survey. Full Text available with Trip Pro

Patient Perceptions of Clear/Almost Clear Skin in Moderate-to-Severe Plaque Psoriasis: Results of the Clear About Psoriasis Worldwide Survey. Therapeutic advances have made the achievement of clear/almost clear skin possible for many patients with moderate-to-severe plaque psoriasis.To determine patient perceptions of the impact of psoriasis and of attaining clear/almost clear skin.Global survey of patients with moderate-to-severe psoriasis.A total of 8338 patients from 31 countries (...) participated. The majority (57%) had not achieved self-assessed clear/almost clear skin with their current therapy, and 56% of those who had not met this goal believed it would be impossible to do so. Among the patients who had clear/almost clear skin, 73% had not initiated their current treatment until >1 year after psoriasis diagnosis, and 28% had to wait >5 years. Eighty-four percent of all respondents experienced discrimination and/or humiliation due to psoriasis, and many reported negative effects

2018 Journal of the European Academy of Dermatology and Venereology

127. Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Full Text available with Trip Pro

Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). 29747219 2018 10 15 1365-2133 179 4 2018 Oct The British journal of dermatology Br. J. Dermatol. Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). 984-986 10.1111/bjd.16737 Kimball A B AB Harvard Medical

2018 British Journal of Dermatology

128. Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT). (Abstract)

Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT). Data on chronic plaque psoriasis severity and its potential clinical and lifestyle implications in the Brazilian population are limited. The primary aim of this study was to assess the clinical severity of plaque psoriasis in Brazil. Further objectives included evaluating potential associations between disease (...) severity and demographic, lifestyle, and clinical characteristics, health-related quality of life (HRQOL), and work productivity.This observational (non-interventional) cross-sectional study was conducted in 26 dermatologic clinics across 11 Brazilian states. Psoriasis severity was assessed using investigator judgment and Finlay's Rule of Tens: a Psoriasis Area and Severity Index (PASI) score >10, a Body Surface Area (BSA) > 10%, or a Dermatology Life Quality Index (DLQI) score >10.Among 1125 patients

2018 Journal of Dermatological Treatment

129. Author Correction to: Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. Full Text available with Trip Pro

Author Correction to: Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. In the original publication, section 5, paragraph 1 was incorrectly published.

2018 American journal of clinical dermatology

130. The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: Analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study). (Abstract)

The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: Analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study). Psychological aspect and quality of life should be considered in treating patients with psoriasis.We sought to ascertain which clinical characteristics including presence of exposed lesions are associated with impairment of health-related quality (...) of life (HRQoL) in patients with psoriasis.The EPI-PSODE study was a nationwide, multicenter, cross-sectional study conducted in Korea that included 1260 adult patients with psoriasis. In addition to clinical characteristics including presence of exposed lesions, data were collected using the Psoriatic Arthritis (PsA) Screening and Evaluation (PASE), Dermatology Life Quality Index (DLQI), MOS 36-Item Short-Form Health Survey (SF-36), Work Productivity and Activity Impairment Questionnaire Psoriasis

2018 Journal of the European Academy of Dermatology and Venereology

131. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. (Abstract)

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD.To assess therapeutic options for patients with psoriasis and concurrent IBD.A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis (...) , psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017. Randomized, controlled, double-blinded studies were selected if available. If not, the next highest level of available evidence was selected.Of the 2282 articles identified, 132 were selected. Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative; colitis, and Crohn's disease. Ustekinumab has demonstrated efficacy in psoriasis, psoriatic

2018 Journal of American Academy of Dermatology

132. Variants of CARD14 are predisposing factors for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese population. (Abstract)

Variants of CARD14 are predisposing factors for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese population. 30387497 2019 02 04 1365-2133 180 2 2019 Feb The British journal of dermatology Br. J. Dermatol. Variants of CARD14 are predisposing factors for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese population. 425-426 10.1111/bjd.17392 Li L L Shandong Provincial Hospital for Skin Diseases, Jinan

2018 British Journal of Dermatology

133. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. Full Text available with Trip Pro

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. Health-related quality of life (HRQoL) may be markedly impaired in patients with moderate-to-severe psoriasis.Our objectives were to compare improvements in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) scores between patients (...) and signs score = 0, DLQI association with PSSD, Investigator's Global Assessment (IGA), and Psoriasis Area and Severity Index (PASI).Significantly greater improvements from baseline DLQI were observed with guselkumab versus placebo (weeks 8 and 16) and versus adalimumab (week 24; p < 0.001). The proportion of patients achieving DLQI 0/1 ("no impact") at week 24 was higher with guselkumab than with adalimumab (58.9 vs. 40.2%; p < 0.001), and more patients attained a ≥ 4-point reduction in DLQI (MCID

2018 American journal of clinical dermatology Controlled trial quality: uncertain

134. Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. (Abstract)

Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. Assessment of disease severity is an essential component of psoriasis management. Moderate-to-severe disease qualifies for systemic treatment but different definitions are used.To analyse the impact of different severity definitions for psoriasis in real-world healthcare.Cross-sectional data on 3274 patients with psoriasis from more than 200 dermatology (...) offices and clinics across Germany were analysed for disease severity based on Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI). The proportions of patients having moderate-to-severe disease were determined accordingly.The proportion of patients meeting the European consensus criteria for moderate-to-severe psoriasis (PASI AND DLQI > 10) was 14·0%, although 45·3% attained at least PASI OR DLQI > 10. Consideration of all patients on systemic drugs as being 'moderate

2018 British Journal of Dermatology

135. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. (Abstract)

Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. Psoriasis is a chronic, inflammatory skin disease and has significant associated morbidity and effect on quality of life. It is important to determine whether dietary interventions help reduce disease severity in patients with psoriatic diseases.To make evidence-based dietary recommendations for adults with psoriasis and/or psoriatic (...) arthritis from the Medical Board of the National Psoriasis Foundation.We used literature from prior systematic reviews as well as additional primary literature from the MEDLINE database from January 1, 2014, to August 31, 2017, that evaluated the impact of diet on psoriasis. We included observational and interventional studies of patients with psoriasis or psoriatic arthritis. The quality of included studies was assessed using the Newcastle-Ottawa scale for observational studies and the Cochrane Risk

2018 JAMA dermatology (Chicago, Ill.)

136. Psoriasis dermatitis: an overlap condition of psoriasis and atopic dermatitis in children. (Abstract)

Psoriasis dermatitis: an overlap condition of psoriasis and atopic dermatitis in children. 30102795 2019 02 12 1468-3083 33 2 2019 Feb Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Psoriasis dermatitis: an overlap condition of psoriasis and atopic dermatitis in children. e74-e76 10.1111/jdv.15213 Kouwenhoven T A TA Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands. Bronckers I M G J IMGJ Department

2018 Journal of the European Academy of Dermatology and Venereology

137. Biological treatment for psoriasis and the risk of herpes zoster: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Full Text available with Trip Pro

Biological treatment for psoriasis and the risk of herpes zoster: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). To describe the risk of herpes zoster (HZ) in patients with psoriasis and its relation to non-biologic systemic therapies or biologic treatment.Psoriasis Longitudinal Assessment and Registry (PSOLAR) is an international, prospective, registry that follows adult patients with psoriasis eligible to receive non-biologic systemic therapies or biologic therapies

2018 Journal of Dermatological Treatment

138. Apremilast for treating moderate to severe plaque psoriasis

Apremilast for treating moderate to severe plaque psoriasis Apremilast for treating moderate to severe plaque psoriasis | Guidance | NICE Apremilast for treating moderate to severe plaque psoriasis Technology appraisal guidance [TA368] Published date: 25 November 2015 Guidance . Explore © NICE [year]. All rights reserved. Subject to .

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

139. Secukinumab for treating moderate to severe plaque psoriasis

Secukinumab for treating moderate to severe plaque psoriasis Secukinumab for treating moder Secukinumab for treating moderate to ate to se sev vere plaque psoriasis ere plaque psoriasis T echnology appraisal guidance Published: 22 July 2015 nice.org.uk/guidance/ta350 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Psoriasis (plaque, moderate to severe) - secukinumab (TA350) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 50Contents Contents 1 Guidance 4 2 The technology 5 3 The company's

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

140. Ustekinumab (Stelara) - for the treatment of chronic moderate to severe plaque psoriasis in adolescent patients

Ustekinumab (Stelara) - for the treatment of chronic moderate to severe plaque psoriasis in adolescent patients AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA455) NICE GUIDANCE ISSUED JULY 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Final Appraisal Recommendation Advice No: 0416 – February 2016 Ustekinumab (Stelara ® ) 45 mg solution for injection, 45 mg and 90 mg solution for injection in pre-filled (...) available), the views of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years. Recommendation of AWMSG Ustekinumab (Stelara ® ) is recommended as an option for use within NHS Wales for the treatment of chronic moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled

2016 All Wales Medicines Strategy Group

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>